ccs-tree

Accurate aneuploidy screening

SelectCCS, available exclusively from the Foundation for Embryonic Competence (FEC), counts all 23 pairs of chromosomes in an embryo to separate embryos with an abnormal number of chromosomes (those with aneuploidy) from embryos with a normal number of chromosomes (those with euploidy).


Testing for too many or too few chromosomes

Humans have 23 pairs of chromosomes, inheriting one copy of each chromosome from each parent. When an embryo is created, it should consist of 23 chromosomes from the egg and 23 chromosomes from the sperm. Sometimes embryos are created with too many or too few chromosomes—a condition known as aneuploidy. Aneuploidy is a major contributor to miscarriage, in vitro fertilization (IVF) failure, and various health conditions, including Down Syndrome.

 

figure-a

SelectCCS helps you minimize your risk of miscarriage and increase your chances of a healthy pregnancy and baby by screening your embryos for the right number of chromosomes before IVF transfer.

SelectCCS helps you minimize your risk of miscarriage and increase your chances of a healthy pregnancy and baby.

SelectCCS is the most validated and proven method of comprehensive chromosome screening available. With greater than 98% accuracy in aneuploidy screening, SelectCSS has been extensively evaluated in more than 20 peer-reviewed research publications.

See the following for steps to the SelectCCS process:

step-1

Step 1

Stimulate and retrieve egg

step-2

Step 2

Develop embryo

step-3

Step 3

Perform trophectoderm biopsy

step-4

Step 4

Receive embryo biopsy

step-5

Step 5

Analyze biopsy

step-6

Step 6

Issue reports

step-7

Step 7

Discuss results with IVF team

step-8

Step 8

Schedule IVF transfer

 

Talk to your doctor, nurse, or genetic counselor about SelectCCS.

 

Watch SelectCCS Video

 

Download SelectCCS Brochure


References: 1. Scott RT Jr, Upham KM, Forman E, et al. Blastocyst biopsy with comprehensive chromosome screening and fresh embryo transfer significantly increases in vitro fertilization implantation and delivery rates: a randomized controlled trial. Fertil Steril. 2013;100(3):697-703. 2. Scott RT Jr, Ferry K, Su J, Tao X, Scott K, Treff NR. Comprehensive chromosome screening is highly predictive of the reproductive potential of human embryos: a prospective, blinded, nonselection study. Fertil Steril. 2012;97(4):870-875.

Advanced detection of aneuploidy for increased success in IVF

Developed by world-renowned physicians and scientists, SelectCCS improves the embryo selection process by detecting aneuploidy in embryos, allowing for the transfer of only euploid embryos and thereby increasing the likelihood of IVF success.

The only fully validated platform for aneuploidy screening, performed on trophectoderm biopsy, SelectCCS is:

  • Greater than 98% accurate in screening for aneuploidy1
  • Demonstrated to provide delivery rates greater than 84% for patients who had SelectCCS testing2
  • Extensively evaluated in over 20 peer-reviewed research publications
  • Proven to have lower false positive rates compared to aCGH

The SelectCCS process

The FEC is committed to working with your practice to provide SelectCCS for your patients. We can support both cryopreserved and fresh cases.

Greater than 98% accuracy in screening for aneuploidy.1

Our laboratory technicians will work closely with your practice to coordinate the sending and receiving of biopsy material. Once biopsies are received in our laboratory, we amplify the DNA using real-time polymerase chain reaction (qPCR) technology—a process that takes only 4 hours to complete—and apply sophisticated bioinformatics algorithms to precisely determine each embryo’s molecular karyotype.

You will receive an in-depth report that will enable you to select euploid embryos for transfer to your patients. Reports are typically generated in 5 to 7 days for cryopreserved cases and next day for fresh transfer.

Trophectoderm biopsy is mandatory for SelectCCS as cleavage stage biopsy has been shown to impair the reproductive potential of an embryo by nearly 40%.3 Prior to sending any samples to the FEC, be sure your embryologists contact the FEC to ensure trophectoderm biopsies.

The FEC is proud to provide embryology training and validation on trophectoderm biopsies prior to your clinic sending any samples to the FEC. Please contact the FEC for more information about this best-in-class service.

See the following for steps to the SelectCCS process:

step-1

Step 1

Stimulate and retrieve egg

step-2

Step 2

Develop embryo

step-3

Step 3

Perform trophectoderm biopsy

step-4

Step 4

Receive embryo biopsy

step-5

Step 5

Analyze biopsy

step-6

Step 6

Issue reports

step-7

Step 7

Discuss results with IVF team

step-8

Step 8

Schedule IVF transfer

Download Physician Flashcard


References: 1. Scott RT Jr, Upham KM, Forman E, et al. Blastocyst biopsy with comprehensive chromosome screening and fresh embryo transfer significantly increases in vitro fertilization implantation and delivery rates: a randomized controlled trial. Fertil Steril. 2013;100(3):697-703. 2. Scott RT Jr, Ferry K, Su J, Tao X, Scott K, Treff NR. Comprehensive chromosome screening is highly predictive of the reproductive potential of human embryos: a prospective, blinded, nonselection study. Fertil Steril. 2012;97(4):870-875. 3. Scott RT Jr, Upham KM, Forman EJ, Zhao T, Treff NR. Cleavage-stage biopsy significantly impairs human embryonic competence potential while blastocyst biopsy does not; a randomized and paired clinical trial. Fertil Steril. 2013;100(3):624-630.